$90 million cancer care center slated for Arizona

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 6
Volume 18
Issue 6

Banner Health and M.D. Anderson Cancer Center will jointly build the M.D. Anderson Banner Cancer Center in Phoenix. The 120,000 square-foot outpatient center will be adjacent to the Banner Gateway Medical Center campus.

Banner Health and M.D. Anderson Cancer Center will jointly build the M.D. Anderson Banner Cancer Center in Phoenix. The 120,000 square-foot outpatient center will be adjacent to the Banner Gateway Medical Center campus.

Services will include medical oncology, radiation oncology, surgical oncology, pathology, laboratory, and diagnostic imaging, as well as other supportive clinical services.

Groundbreaking is scheduled for later this year and the facility is set to open in late 2011. It will be modeled after M.D. Anderson’s Houston outpatient clinics, which feature areas devoted to single disease states. The project will be funded by Banner Health.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Related Content